LTP — Ltr Pharma Income Statement
0.000.00%
Last trade - 00:00- AU$80.89m
- AU$61.23m
- AU$1.62m
Annual income statement for Ltr Pharma, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.009 | 0 | 0.049 | 2.1 | 1.62 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1.02 | 1.41 | 6.46 | 7.28 | 14.4 |
| Operating Profit | -1.01 | -1.41 | -6.41 | -5.18 | -12.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.03 | -1.45 | -6.95 | -5.59 | -14.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.03 | -1.45 | -6.95 | -5.59 | -14.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.03 | -1.45 | -6.95 | -5.59 | -14.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.03 | -1.45 | -6.95 | -5.59 | -14.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.008 | -0.011 | -0.048 | -0.033 | -0.077 |
| Dividends per Share |